NCT07253324

ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENX-104 in Participants With Major Depressive Disorder With Anhedonia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Engrail Therapeutics INC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ENX-104 in participants with major depressive disorder with anhedonia (aMDD).

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	ENX-104	Oral Solution
DRUG	Placebo	Oral solution

Timeline

• Start date: 2025-02-17
• Primary completion: 2025-11-26
• Completion: 2025-11-26
• First posted: 2025-11-28
• Last updated: 2025-12-31

Locations

4 sites across 1 country: United Kingdom